Literature DB >> 1419627

The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients.

A C Häffner1, C Garbe, G Burg, P Büttner, C E Orfanos, G Rassner.   

Abstract

The prognostic value of the TNM classifications of the UICC dated 1978 and 1987, was investigated in a population of 2,495 patients who were followed up over the long term. In the case of primary melanoma, Breslow's tumour thickness proved to be the most powerful predictor of patient survival in multivariate analysis, while the significance of Clark's level ranged after that of both localisation of the primary tumour and the sex of the patient. The continuous proportional relationship between tumour thickness and risk of death makes it possible to regrade thickness groups. Grading cutoffs at 1, 2 and 4 millimetres, with no account being taken of depth of invasion, proved to be particularly favourable for a classification in accordance with prognostic criteria. In advanced stages of the disease, the outcome of locoregional and distant metastasis is significantly different; and furthermore in the case of locoregional metastasis, in-transit and satellite metastases exert a significantly better prognosis than regional lymph node involvement. Isolated juxtaregional lymph node metastases occurred primarily or during the course of the observation period in only 19 patients of our group, and, in comparison with visceral metastases, proved to have only an insignificantly better prognosis. For this reason, it would appear meaningful to assign them to a common stage. On the basis of these results, proposals are made for modifications of the TNM classification.

Entities:  

Mesh:

Year:  1992        PMID: 1419627      PMCID: PMC1977994          DOI: 10.1038/bjc.1992.373

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  17 in total

1.  Maximum utilization of the life table method in analyzing survival.

Authors:  S J CUTLER; F EDERER
Journal:  J Chronic Dis       Date:  1958-12

2.  Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.

Authors:  A Breslow
Journal:  Ann Surg       Date:  1970-11       Impact factor: 12.969

3.  The natural break points for primary-tumor thickness in clinical Stage I melanoma.

Authors:  C L Day; R A Lew; M C Mihm; M N Harris; A W Kopf; A J Sober; T B Fitzpatrick
Journal:  N Engl J Med       Date:  1981-11-05       Impact factor: 91.245

Review 4.  Prognostic factors in thin cutaneous malignant melanoma.

Authors:  S M Salman; G S Rogers
Journal:  J Dermatol Surg Oncol       Date:  1990-05

5.  Semi-solid cultures of primary melanomas and their correlation with histopathological features.

Authors:  P C Vincent; R M Joyce; G Croaker; G A Young; G W Milton; W H McCarthy
Journal:  Pathology       Date:  1985-04       Impact factor: 5.306

6.  Malignant melanoma. Changing trends in factors influencing metastasis-free survival from 1964 to 1982.

Authors:  K T Drzewiecki; H Frydman; K Andersen; H Poulsen; C Ladefoged; P Vibe
Journal:  Cancer       Date:  1990-01-15       Impact factor: 6.860

7.  Influence of anatomic location on prognosis of malignant melanoma: attempt to verify the BANS model.

Authors:  G S Rogers; A W Kopf; D S Rigel; M L Levenstein; R J Friedman; M N Harris; F M Golomb; P Hennessey; S L Gumport; D F Roses
Journal:  J Am Acad Dermatol       Date:  1986-08       Impact factor: 11.527

8.  Cutaneous malignant melanoma. II. The natural history and prognostic factors influencing the development of stage II disease.

Authors:  D H Berdeaux; F L Meyskens; B Parks; T Tong; L Loescher; T E Moon
Journal:  Cancer       Date:  1989-04-01       Impact factor: 6.860

9.  Tumor thickness and prognosis in clinical stage I malignant melanoma.

Authors:  C P Karakousis; L J Emrich; U Rao
Journal:  Cancer       Date:  1989-10-01       Impact factor: 6.860

10.  Cutaneous malignant melanoma (Arizona Cancer Center experience). I. Natural history and prognostic factors influencing survival in patients with stage I disease.

Authors:  F L Meyskens; D H Berdeaux; B Parks; T Tong; L Loescher; T E Moon
Journal:  Cancer       Date:  1988-09-15       Impact factor: 6.860

View more
  4 in total

Review 1.  Regional therapies for in-transit disease.

Authors:  Paul J Speicher; Claire H Meriwether; Douglas S Tyler
Journal:  Surg Oncol Clin N Am       Date:  2015-01-30       Impact factor: 3.495

2.  Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group.

Authors:  P Terheyden; A-K Kortüm; H-J Schulze; B Durani; R Remling; C Mauch; V Junghans; D Schadendorf; U Beiteke; M Jünger; J C Becker; E-B Bröcker
Journal:  J Cancer Res Clin Oncol       Date:  2007-03-03       Impact factor: 4.322

Review 3.  The prognostic significance of the clinical and histological parameters in primary cutaneous melanoma patients.

Authors:  Mihaela Antohe; Anastasia Coman; Gabriela Turcu; Roxana Ioana Nedelcu; Alice Brinzea; Mihaela Balaban; Andreea Moroianu; Lorena Manea; Ionela Hulea; Elena Balasescu; Sabina Andrada Zurac; Mirela Cioplea; Cristiana Popp; Luciana Nichita; Daniela Adriana Ion
Journal:  Med Pharm Rep       Date:  2022-07-26

Review 4.  Staging of cutaneous melanoma.

Authors:  P Mohr; A M M Eggermont; A Hauschild; A Buzaid
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.